Synthetic Biology Group, MIT Synthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA, United States; Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA, United States; Department of Biological Engineering, and Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, United States; Broad Institute of MIT and Harvard, Cambridge, MA, United States; Harvard Biophysics Program, Harvard University, Boston, MA, United States; The Center for Microbiome Informatics and Therapeutics, Cambridge, MA, United States.
S-Inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande, MS, Brazil.
Pharmacol Ther. 2017 Oct;178:132-140. doi: 10.1016/j.pharmthera.2017.04.002. Epub 2017 Apr 21.
Antimicrobial peptides (AMPs) have evolved through billions of years as part of our innate immune system. These agents are produced by various cells throughout the human body and play important roles in our ability to respond to infections. In this review, we outline evidence linking AMP expression with a range of inflammatory and autoimmune human diseases. Finally, we highlight the promise of endogenous AMP induction for the treatment of disease (i.e., host-directed therapy) and briefly mention the different peptide drugs that are currently undergoing clinical trials.
抗菌肽 (AMPs) 是我们先天免疫系统的一部分，经过数十亿年的进化而来。这些物质由人体的各种细胞产生，在我们应对感染的能力中发挥着重要作用。在这篇综述中，我们概述了 AMP 表达与一系列炎症性和自身免疫性人类疾病相关的证据。最后，我们强调了内源性 AMP 诱导在治疗疾病（即宿主导向治疗）方面的前景，并简要提及了目前正在进行临床试验的不同肽类药物。
